Zobrazeno 1 - 10
of 179
pro vyhledávání: '"Ming Chih Chang"'
Autor:
Chi Wang, Nai-Wen Su, Kate Hsu, Chen-Wei Kao, Ming-Chih Chang, Yi-Fang Chang, Ken-Hong Lim, Yi-Hao Chiang, Yu-Cheng Chang, Meng-Ta Sung, Hsueh-Hsia Wu, Caleb G. Chen
Publikováno v:
Molecular Medicine, Vol 30, Iss 1, Pp 1-13 (2024)
Abstract Background Despite the advances of therapies, multiple myeloma (MM) remains an incurable hematological cancer that most patients experience relapse. Tumor angiogenesis is strongly correlated with cancer relapse. Human leukocyte antigen G (HL
Externí odkaz:
https://doaj.org/article/68855d57d6044c93889ec0390a9f0a6d
Autor:
Peter S. Chang, Yi-Chun Chen, Wei-Kai Hua, Jeff C. Hsu, Jui-Cheng Tsai, Yi-Wun Huang, Yi-Hsin Kao, Pei-Hua Wu, Po-Nan Wang, Yi-Fang Chang, Ming-Chih Chang, Yu-Cheng Chang, Shiou-Ling Jian, Jiann-Shiun Lai, Ming-Tain Lai, Wei-Cheng Yang, Chia-Ning Shen, Kuo-Lan Karen Wen, Sareina Chiung-Yuan Wu
Publikováno v:
PLoS ONE, Vol 19, Iss 8 (2024)
Externí odkaz:
https://doaj.org/article/a24dce73854148dc9828f7489ea2bfaa
Autor:
Yu-Cheng Chang, Yi-Hao Chiang, Kate Hsu, Chih-Kuang Chuang, Chen-Wei Kao, Yi-Fang Chang, Ming-Chih Chang, Ken-Hong Lim, Hung-I Cheng, Yen-Ning Hsu, Caleb G. Chen
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 11, Pp 1-10 (2021)
Abstract Tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the frontline treatments in chronic myeloid leukemia (CML). Growing evidence has shown that TKIs also enhance immunity. Since gamma-delta T (γδT) cells possess the potent anticancer
Externí odkaz:
https://doaj.org/article/9de7eaa081b649b584d078d1f35041b7
Publikováno v:
Maxillofacial Plastic and Reconstructive Surgery, Vol 39, Iss 1, Pp 1-5 (2017)
Abstract Background Rehabilitation of normal function and form is essential in cleft lip repair. In 2005, Dr. David M. Fisher introduced an innovative method, named “an anatomical subunit approximation technique” in unilateral cleft lip repair. A
Externí odkaz:
https://doaj.org/article/c3b422e0a06c463db288daa40ae69b45
Autor:
Shang-Yi Huang, Tsai-Yun Chen, Ching-Yuan Kuo, Yeu-Chin Chen, Sheng-Fung Lin, Ming-Chih Chang, Xinzhu Lv, Betty Yang, Cheng-Shyong Chang
Publikováno v:
Oncology Reviews, Vol 13, Iss 1 (2019)
Bortezomib is a proteasome inhibitor, approved for treating newly diagnosed and relapsed multiple myeloma (MM). This realworld, multicenter, observational, non-interventional study of bortezomib was designed to collect and analyze prospective data in
Externí odkaz:
https://doaj.org/article/1d2c495198cc4729af7bf7c8c4354a95
Autor:
Bor-Sheng Ko1, Ming-Chih Chang2 mmhdonald@yahoo.com.tw, Tzeon-Jye Chiou3, Te-Kau Chang4, Yeu-Chin Chen5, Sheng-Fung Lin6, Cheng-Shyong Chang7, Yin-Che Lu8, Su-Peng Yeh9, Tsai-Yun Chen10, Wei-Shou Hwang11
Publikováno v:
Hematology. 2019, Vol. 24 Issue 1, p247-254. 8p.
Autor:
Wen-Li Hwang, Tsung-Chih Chen, Hsuan-Yu Lin, Ming-Chih Chang, Pei-Ching Hsiao, Li-Yuan Bai, Ching-Yuan Kuo, Yeu-Chin Chen, Ta-Chih Liu, Jyh-Pyng Gau, Po-Nan Wang, Wei-Shou Hwang, Ming-Chung Kuo, Chun-Yu Liu, Yi-Chang Liu, Ming-Chun Ma, Nai-Wen Su, Chuan-Cheng Wang, Yi-Ying Wu, Ming Yao, Su-Peng Yeh, Hao-Wei Cheng, Yee-Ming Lee, Fan-Chen Ku, Jih-Luh Tang
Publikováno v:
International Journal of Hematology. 115:704-712
Nilotinib has been approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph
Publikováno v:
International Journal of Gerontology; Jul2022, Vol. 16 Issue 3, p167-174, 8p
Autor:
Ming-Chung Kuo, Chien-Chin Lin, Hsuan-Yu Lin, Jyh-Pyng Gau, Ming-Chung Wang, Ming-Chih Chang, Tsung-Chih Chen, Shih-Peng Yeh, Yeu-Chin Chen, Cih-En Huang, I-Ju Chiang, Chu-Han Chung, Yee-Ming Lee, Fan-Chen Ku, Cheng-Shyong Chang
Publikováno v:
Blood. 140:9709-9710
Autor:
Peter S. Chang, Yi-Chun Chen, Wei-Kai Hua, Jeff C. Hsu, Jui-Cheng Tsai, Yi-Wun Huang, Yi-Hsin Kao, Pei-Hua Wu, Yi-Fang Chang, Ming-Chih Chang, Yu-Cheng Chang, Shiou-Ling Jian, Jiann-Shiun Lai, Ming-Tain Lai, Wei-Cheng Yang, Chia-Ning Shen, Kuo-Lan Karen Wen, Sareina Chiung-Yuan Wu
BackgroundCD19-targeted chimeric antigen receptor therapies (CAR19) have driven a paradigm shift in the treatment of relapsed/refractory B-cell malignancies. However, >50% of CAR19-treated patients experienced progressive disease mainly due to antige
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70c7124184947136f175986840868698
https://doi.org/10.1101/2022.05.03.490475
https://doi.org/10.1101/2022.05.03.490475